Toll-like receptor agonist formulations and their use
The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
1. A stable liquid formulation comprising a Toll-like receptor (TLR) agonist and a β-cyclodextrin, wherein said agonist is (1E,4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide or a pharmaceutically acceptable salt thereof, and the formulation is an aqueous solution comprising the agonist at a concentration of from about 1 mg/ml to about 40 mg/ml and the β-cyclodextrin at a concentration of from about 1% to about 30% weight/volume, and the pH of the formulation is from about 5.0 to about 7.
2. The formulation of claim 1 , wherein the β-cyclodextrin is sulfobutyl ether β-cyclodextrin.
3. The formulation of claim 1 , wherein the formulation comprises from about 5%-15% weight/volume of the β-cyclodextrin.
4. The formulation of claim 1 , wherein the agonist is formulated at a concentration of from about 2 mg/ml to about 15 mg/ml.
5. A method for treating cancer in a subject comprising administering to the subject a stable formulation of claim 1 , and the cancer is selected from colon carcinoma, ovarian cancer, breast cancer, head and neck cancer, renal cancer, bladder cancer, hepatocellular cancer and lymphoma.
6. The method of claim 5 , wherein the TLR agonist is formulated at a concentration of at least 2 mg/ml.
7. The method of claim 5 , wherein the formulation is suitable for administration to the subject by injection.
8. The method of claim 5 , wherein the TLR agonist is administered to the subject at weekly or biweekly intervals.
9. A method for treating an infectious disease in a subject comprising administering to the subject a stable formulation of claim 1 .
10. A method for treating atopic dermatitis in a subject comprising administering to the subject a stable formulation of claim 1 .
11. A pharmaceutical pack or kit comprising one or more containers filled with a stable formulation of claim 1 .
12. The formulation of claim 1 , wherein the formulation is stable at about 20-30° C. at concentrations up to 40 mg/ml for at least 2 weeks.
13. The formulation of claim 1 , wherein the pH is about 6.5.
14. The formulation of claim 1 , wherein the formulation is an aqueous solution comprising the agonist at a concentration of from about 2 mg/ml to about 15 mg/ml and the β-cyclodextrin at a concentration of from about 5% to about 15% weight/volume, and the pH of the formulation is from about 5.0 to about 7.
15. A method for treating cancer in a subject in need thereof comprising administering to the subject the formulation of claim 14 , wherein the cancer is selected from colon carcinoma, ovarian cancer, breast cancer, head and neck cancer, renal cancer, bladder cancer, hepatocellular cancer and lymphoma.